Stocks · News reference
Wedbush analyst David Nierengarten initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating and announces Price Target of $35.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
BMO Capital analyst David Lebowitz initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating and announces Price Target of $37.
Read original at benzingaBank of America screened its AI baskets for Buy-rated stocks down over 20% from highs. Micron carries the widest gap to target.
Read original at benzingaAktis Oncology (NASDAQ:AKTS) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.43) by 2.33 percent. This is a 98.03 percent increase over losses of $(22.39) per share from
Read original at benzinga